HRTX
$0.87
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.
Recent News
Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Heron Therapeutics, Inc.'s Q4 2025 earnings call
Heron Therapeutics Inc (HRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
Heron Therapeutics Inc (HRTX) surpasses revenue expectations while navigating oncology declines and regulatory hurdles.
Heron Therapeutics Q4 Earnings Call Highlights
Heron Therapeutics (NASDAQ:HRTX) reported fourth-quarter and full-year 2025 results while outlining plans to increase commercial investment in 2026 to build on what management described as an inflection in acute care demand that emerged earlier than expected. 2025 financial results and profitabilit
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Heron Therapeutics: Q4 Earnings Snapshot
On a per-share basis, the Cary, North Carolina-based company said it had a loss of 2 cents. The pharmaceutical company posted revenue of $40.6 million in the period. For the year, the company reported a loss of $20.2 million, or 12 cents per share.